Exagen’s Patented Biomarker PC4d May Help Predict Risk of Blood Clots in SLE, Study Shows
Platelet-bound C4d (PC4d), one of Exagen‘s patented biomarkers, may be used along with other available biomarkers to estimate the risk of thrombosis — the formation of blood clots — among people with systemic lupus erythematosus (SLE), a study shows. The study, “Platelet-bound C4d, low C3…